Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Blood Type and Cognitive Impairment Risk

Blood group AB and higher factor VIII are associated with increased incidence of cognitive impairment.

Myelofibrosis Drug Granted Orphan Drug Status

Promedior announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for PRM-151 for the treatment of myelofibrosis.

Rixubis Pediatric Hem. B Indication

The FDA has approved Rixubis for routine prophylaxis, control, and prevention of bleeding episodes, and perioperative management in children with hemophilia B.

InnoPharma Approved

InnoPharma has announced that it has received approval on its ANDA for Decitabine for Injection, a generic version of Eisai's Dacogen.

Myelofibrosis Drug: Orphan Status

Promedior announced that the FDA has granted Orphan Drug designation for PRM-151 for the treatment of myelofibrosis.

First Treatment for Common Anemia

A recent study has demonstrated potential for lexaptepid pegol as the first treatment for anemia of inflammation, the most common form of anemia.

Hematological Reference Values

Review this chart on 'Hematological Reference Values' for quick information when you need it.

New Drug Product: Alprolix

Prevention and control of bleeding in hemophilia B.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Vertebroplasty is effective for managing myelomatous VCFsExternal web site

Nurse awareness of this treatment option and the patient selection criteria may be a significant ...

CE 0.60 Credits

Lung cancer: Guidelines, new drugs improve outcomesExternal web site

Advances in screening and FDA approval of two new targeted therapies have significantly impacted outcomes ...

CE 0.90 Credits

Sign Up for Free e-newsletters